Your browser doesn't support javascript.
loading
Predictors for progression in amyotrophic lateral sclerosis associated to SOD1 mutation: insight from two population-based registries.
Martinelli, Ilaria; Ghezzi, Andrea; Zucchi, Elisabetta; Gianferrari, Giulia; Ferri, Laura; Moglia, Cristina; Manera, Umberto; Solero, Luca; Vasta, Rosario; Canosa, Antonio; Grassano, Maurizio; Brunetti, Maura; Mazzini, Letizia; De Marchi, Fabiola; Simonini, Cecilia; Fini, Nicola; Vinceti, Marco; Pinti, Marcello; Chiò, Adriano; Calvo, Andrea; Mandrioli, Jessica.
Afiliación
  • Martinelli I; Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
  • Ghezzi A; Clinical and Experimental Medicine Ph.D. Program, University of Modena and Reggio Emilia, Modena, Italy.
  • Zucchi E; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Gianferrari G; Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy. elibettizucchi@gmail.com.
  • Ferri L; Neuroscience PhD Program, University of Modena and Reggio Emilia, Modena, Italy. elibettizucchi@gmail.com.
  • Moglia C; Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
  • Manera U; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Solero L; Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
  • Vasta R; Neuroscience PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
  • Canosa A; Department of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
  • Grassano M; Department of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
  • Brunetti M; Department of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
  • Mazzini L; Department of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
  • De Marchi F; Department of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
  • Simonini C; SC Neurologia 1U, AOU Città della Salute e della Scienza of Torino, Turin, Italy.
  • Fini N; Department of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
  • Vinceti M; SC Neurologia 1U, AOU Città della Salute e della Scienza of Torino, Turin, Italy.
  • Pinti M; SC Neurologia 1U, AOU Città della Salute e della Scienza of Torino, Turin, Italy.
  • Chiò A; Neurology Unit, ALS Center, AOU Maggiore della Carità and University of Piemonte Orientale, Novara, Italy.
  • Calvo A; Neurology Unit, ALS Center, AOU Maggiore della Carità and University of Piemonte Orientale, Novara, Italy.
  • Mandrioli J; Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
J Neurol ; 270(12): 6081-6092, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37668704
ABSTRACT

BACKGROUND:

Uncovering distinct features and trajectories of amyotrophic lateral sclerosis (ALS) associated with SOD1 mutations (SOD1-ALS) can provide valuable insights for patient' counseling and stratification for trials, and interventions timing. Our study aims to pinpoint distinct clinical characteristics of SOD1-ALS by delving into genotype-phenotype correlations and factors that potentially impact disease progression.

METHODS:

This is a retrospective observational study of a SOD1-ALS cohort from two Italian registers situated in the regions of Emilia-Romagna, Piedmont and Valle d'Aosta.

RESULTS:

Out of 2204 genotyped ALS patients, 2.5% carried SOD1 mutations, with a MF ratio of 0.83. SOD1-ALS patients were younger, and more frequently reported a family history of ALS and/or FTD. SOD1-ALS had a longer survival compared to patients without ALS-associated gene mutations. However, here was considerable variability in survival across distinct SOD1 mutations, with an average survival of less than a year for the L39V, G42S, G73S, D91N mutations. Among SOD1-ALS, multivariate analysis showed that, alongside established clinical prognostic factors such as advanced age at onset and high progression rate at diagnosis, mutations located in exon 2 or within highly conserved gene positions predicted worse survival. Conversely, among comorbidities, cancer history was independently associated with longer survival.

INTERPRETATION:

Within the context of an overall slower disease, SOD1-ALS exhibits some degree of heterogeneity linked to the considerable genetic diversity arising from the multitude of potential mutations sites and specific clinical prognostic factors, including cancer history. Revealing the factors that modulate the phenotypic heterogeneity of SOD1-ALS could prove advantageous in improving the efficacy of upcoming therapeutic approaches.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Amiotrófica Lateral / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Neurol Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Amiotrófica Lateral / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Neurol Año: 2023 Tipo del documento: Article País de afiliación: Italia